Risperidone dosing in children and adolescents with autistic disorder: a double-blind, placebo-controlled study (Q50303584)

2 March 2018

title

Risperidone dosing in children and adolescents with autistic disorder: a double-blind, placebo-controlled study (English)

1 reference

2 March 2018

0 references

1 reference

1 reference

1 reference

Michael Aman

1 reference

2 March 2018

author name string

Justine M Kent

1 reference

2 March 2018

Stuart Kushner

1 reference

2 March 2018

Xiaoping Ning

1 reference

2 March 2018

Keith Karcher

1 reference

2 March 2018

Seth Ness

1 reference

2 March 2018

Jaskaran Singh

1 reference

2 March 2018

David Hough

1 reference

2 March 2018

language of work or name

English

0 references

publication date

1 August 2013

1 reference

2 March 2018

Journal of Autism and Developmental Disorders

published in

1 reference

2 March 2018

volume

1 reference

2 March 2018

issue

1 reference

2 March 2018

page(s)

1773-1783

1 reference

2 March 2018

Acute and long-term safety and tolerability of risperidone in children with autism

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS10803-012-1723-5

Plasma pharmacokinetic characteristics of risperidone and their relationship to saliva concentrations in children with psychiatric or neurodevelopmental disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10803-012-1723-5

Effects of short- and long-term risperidone treatment on prolactin levels in children with autism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10803-012-1723-5

Parent-defined target symptoms respond to risperidone in RUPP autism study: customer approach to clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10803-012-1723-5

A rating scale for drug-induced akathisia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10803-012-1723-5

The genetics of autistic disorders and its clinical relevance: a review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10803-012-1723-5

Risperidone treatment of children with autistic disorder: effectiveness, tolerability, and pharmacokinetic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10803-012-1723-5

Autistic disorder and viral infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10803-012-1723-5

Does cerebellar injury in premature infants contribute to the high prevalence of long-term cognitive, learning, and behavioral disability in survivors?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10803-012-1723-5

Risperidone treatment in children and adolescents with autism: short- and long-term safety and effectiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10803-012-1723-5

Risperidone in children with autism and serious behavioral problems

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10803-012-1723-5

An open trial of risperidone in young autistic children

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10803-012-1723-5

Risperidone improves behavioral symptoms in children with autism in a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10803-012-1723-5

Searching for ways out of the autism maze: genetic, epigenetic and environmental clues

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10803-012-1723-5

A randomized, double-blind, placebo-controlled study of risperidone maintenance treatment in children and adolescents with disruptive behavior disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10803-012-1723-5

Risperidone treatment of autistic disorder: longer-term benefits and blinded discontinuation after 6 months

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10803-012-1723-5

Children's Yale-Brown Obsessive Compulsive Scale: reliability and validity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10803-012-1723-5

Developmental deficits in social perception in autism: the role of the amygdala and fusiform face area

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10803-012-1723-5

Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10803-012-1723-5

Tracing the Origins of Autism: A Spectrum of New Studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10803-012-1723-5

Population pharmacokinetics of oral risperidone in children, adolescents and adults with psychiatric disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10803-012-1723-5

Long-term effects of risperidone in children with autism spectrum disorders: a placebo discontinuation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10803-012-1723-5

Metabolic side effects of antipsychotic medication

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10803-012-1723-5

Long-term safety and efficacy of risperidone for the treatment of disruptive behavior disorders in children with subaverage IQs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10803-012-1723-5

Metabolic changes associated with antipsychotic use

21 January 2018

1 reference

12 December 2020

Treatment of aggression in children and adolescents with autism and conduct disorder.

1 reference

12 December 2020

The aberrant behavior checklist: a behavior rating scale for the assessment of treatment effects.

1 reference

12 December 2020

Psychometric characteristics of the aberrant behavior checklist

1 reference

12 December 2020

A rating scale for extrapyramidal side effects

1 reference

12 December 2020

Prolactin levels during long-term risperidone treatment in children and adolescents

1 reference

12 December 2020

10.1007/S10803-012-1723-5

Identifiers

DOI

1 reference

2 March 2018

1 reference

2 March 2018